For decades, Grifols grew rich from an empire built on blood. Founded by a plucky scientist and his two sons in the years after the Spanish Civil War, the company made a series of breakthroughs that ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator ...

Grifols plans to release Phase III results of its long-term albumin treatment designed to increase survival time in patients with decompensated cirrhosis and ascites in 2024, says chief scientific ...

Grifols shares plunged by a further 14% on Wednesday following publication of another report from short seller Gotham City Research, raising additional questions about the Barcelona medicine maker ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying ...

Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. The CNMV declined to comment about the letter. Grifols shares were down around ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...